The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Diagnostic testing for active SARS-CoV-2 infection, testing for past infection, and analyses of potential vaccines are critical enablers of the treatment, understanding, and control of SARS-CoV-2. Diagnostic and other tests have also been key components of recent fights against viruses such as MERS-CoV, Zika, Influenza H7N9, and Ebola. Nucleic acid tests, serological tests, serum antibody tests, and neutralizing serum antibody tests are examples of population testing that have been employed for COVID-19 diagnostic testing. The current tests that have been given approval or authorization by Regulatory Authorities and are being used by vaccine manufacturers have been developed and reviewed in a timecritical fashion. There are many potential learnings regarding development, commercialization, supply, and regulation that can be taken from the SARS-CoV2-related activities of the past year and from work on previous pandemic diagnostics. These leanings can potentially be applied to both additional SARSCoV-2 undertakings and activities related to future pandemics; across industry, regulatory, and academic environments; and to diagnostics, vaccines, and therapeutics. At the same time, there remain many questions and points for further discussion. This session will discuss evolution and use of SARS-CoV-2 diagnostics and other tests from industry, regulatory, and patient care perspectives.